Positive Phase III results from the BRIGHTE study of fostemsavir

27 October 2017

ViiV Healthcare, the global specialist HIV company majority-owned by UK pharma major GlaxoSmithKline (LSE: GSK), with Pfizer and Shionogi as shareholders, today announced results from the Phase III BRIGHTE study of fostemsavir in heavily treatment-experienced (HTE) patients with HIV-1 infection.

Following one week of treatment, HTE patients receiving fostemsavir added to a failing regimen experienced a greater reduction in HIV-1 viral load compared to patients receiving placebo, demonstrating statistical superiority of fostemsavir over placebo (0.79 log10 c/mL versus 0.17 log10 c/mL; p<0.0001).

GSK and ViiV, which was established in 2009, acquired rights to fostemsavir in December 2015, as part of a $1.4 billion deal with Bristol-Myers Squibb (NYSE: BMY). While under the ownership of the US pharma major, fostemsavir received Breakthrough Therapy designation from the US Food and Drug Administration and that time was expected to be filed for regulatory approval in 2018.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK